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Using retrospective (n  200) and prospective (n  150) nasopharyngeal specimens, we evaluated the Nanosphere Verigene
RV and the Focus Diagnostics Simplexa Flu A/B & RSV tests. Overall, RV demonstrated sensitivities and specificities of
96.6% and 100% for influenza A virus, 100% and 99.7% for influenza B virus, and 100% and 100% for respiratory syncytial virus
(RSV), while the Simplexa test sensitivities and specificities were 82.8 and 99.7%, 76.2 and 100%, and 94.6 and 100%,
respectively.
Viral respiratory infections are a leading cause of morbidity andmortality, especially during the winter months, with the most
severe infections being attributed to influenza virus and respira-
tory syncytial virus (RSV). The low sensitivity of rapid antigen
tests (1, 2) and the delayed time to result of viral culture combined
with the improved sensitivity afforded by molecular methods has
led to an increase of FDA-cleared tests and systems designed to
detect these viruses. The Nanosphere Verigene Respiratory Virus
Plus (RV) test (Northbrook, IL) is an FDA-cleared random ac-
cess molecular test based on nanoparticle technology that does not
require pre-extraction of specimens (3). The RV test detects
influenza A virus, influenza B virus, RSV A, and RSV B while also
providing influenza A virus-specific typing results for 2009 H1N1,
H3, and H1. Also FDA cleared, the Focus Diagnostics Simplexa
Flu A/B & RSV kit (Cypress, CA) is a multiplex real-time PCR
assay that requires pre-extraction and batched testing. The Simpl-
exa test provides results for influenza A virus, influenza B virus,
and RSV but does not subtype influenza A virus. Both tests are
FDA cleared for use on nasopharyngeal swabs.
We conducted a side-by-side, retrospective and prospective
evaluation of the Nanosphere Verigene system running the RV
test and the Focus Diagnostics Simplexa Flu A/B & RSV kit on an
integrated cycler to determine the respective performance charac-
teristics. Positive and negative specimens were originally identi-
fied by routine clinical testing by Xpert Flu A/B (n  72; Cepheid,
Sunnyvale, CA), Luminex RVP (n  46; Austin, TX), or our lab-
oratory-developed tests (LDTs) (n  82). We have previously
shown that Xpert and RVP are 100% specific for the viruses tested
compared to our LDTs (reference 4 and our unpublished data).
All discrepant results were simultaneously tested by our influenza
A and B virus (4) and RSV (5) LDTs, in addition to repeating both
test methods (RV and Simplexa). The RV and Simplexa tests
were performed according to the manufacturers’ instructions.
The retrospective evaluation included 200 nasopharyngeal (NP)
specimens (192 NP swabs and 8 NP aspirates/washes), of which 55
were positive for influenza A virus (21 2009 H1N1, 23 H3, and 11
H1), 21 were positive for influenza B virus, 42 were positive for RSV
(21 each of A and B), and 82 were negative for influenza and RSV.
Specimens were collected between 2005 and 2012 (17 were collected
prior to 2009), stored at 70°C, thawed once, and kept refrigerated
until testing. For the prospective testing, 150 consecutive nasopha-
ryngeal samples (144 NP swabs and 6 NP aspirates) were tested by the
RV assay upon receipt at the lab; specimens were stored at 4°C and
tested by the Simplexa assay and our LDTs once a batch had accumu-
lated. All specimens were vortexed prior to testing. The prospective
specimens were ordered for only influenza and/or RSV testing and
collected between January and June 2012. Of the prospective samples,
three were positive for influenza A virus (2 2009 H1N1 and 1 H3) and
51 were positive for RSV (44 A and 7 B), while 96 were negative. Due
to the relative lack of influenza activity during the prospective study
and the lack of statistically significant differences in RSV sensitivity in
comparisons of retrospective and prospective studies, only cumula-
tive data (n  350) are presented. No inhibition was observed in any
specimen type, even those not FDA cleared (e.g., NP aspirates and
washes). Fisher’s exact test for 2-by-2 contingency table analysis was
performed and confidence intervals were determined using Graph-
Pad (La Jolla, CA); a two-tailed Student’s t test was performed using
Excel (see Table 2). P values of 0.05 were considered statistically
significant.
The combined results of the retrospective and prospective analy-
ses are shown in Table 1. Although the difference did not reach sta-
tistical significance, the Verigene RV test was more sensitive for
RSV detection than the Simplexa test (100% versus 94.6%, respec-
tively; P  0.059). However, for the detection of influenza A virus
(96.6% versus 82.8%; P  0.029) and influenza B virus (100% versus
76.2%; P  0.048), the sensitivity of the Verigene RV assay was
superior. Both tests were highly specific. The Nanosphere test had one
false-positive influenza B virus result, and the Simplexa test had one
false-positive influenza A virus result, resulting in overall specificities
of 99.4% for both assays. Although not FDA cleared, NP aspirates
(n  14) performed comparably to NP swabs.
Received 21 September 2012 Returned for modification 19 October 2012
Accepted 2 November 2012
Published ahead of print 14 November 2012
Address correspondence to Melissa B. Miller, mbmiller@unch.unc.edu.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.02504-12
352 jcm.asm.org Journal of Clinical Microbiology p. 352–353 January 2013 Volume 51 Number 1
Based on the limits of detection (measured as 50% tissue cul-
ture infective doses [TCID50]/ml) stated in the respective package
inserts, we expected the two assays to perform similarly. However,
direct comparison is difficult due to differences in strains used for
limit-of-detection studies. Therefore, we evaluated the cycle
threshold (CT) values of our LDT to see if a correlation could be
made between samples missed by the test assay and their LDT CT
value. The results of these analyses are shown in Table 2. We note
that some positive specimens were originally identified using
methods other than our LDTs and were not included in the CT
analysis (n  14). There was a statistically significant difference
between the mean LDT CT values for detected positive specimens
and the mean LDT CT values for false-negative influenza A virus
specimens by both RV (P  0.0039) and Simplexa (P  0.0001)
and false-negative RSV specimens by Simplexa (P  0.0001).
Likely due to the relatively low numbers of influenza B virus-
positive specimens, the difference in CT values for Simplexa did
not reach statistical significance (P  0.0555). No influenza B
virus or RSV samples were called falsely negative by the RV
assay. These data suggest that the false-negative results obtained
by RV and Simplexa are due to the lower analytical sensitivities
of these tests than of our LDTs.
In terms of workflow, the two systems are significantly differ-
ent. As an on-demand modular system using integrated extrac-
tions, the Verigene RV assay requires 5 min of hands-on time
per specimen and reports results in 2.5 h. However, only one sam-
ple can be run per module at one time. In contrast, the Simplexa
test requires 45 min of hands-on time (including pre-extraction of
up to 24 samples) but still offers results in 2.5 h. However, since
the Simplexa test is better performed as a batch test, there is the
potential for a higher throughput. The throughput of the RV
test depends on the number of Verigene processors. Both assays
offer results faster than most LDT real-time RT-PCR assays, which
require pre-extraction and batch testing. The average reagent cost
per test in 2012 U.S. dollars is $70 for the RV and $49 for the
Simplexa assay (including extraction). As noted above, the labor
costs vary significantly for the two assays.
To our knowledge, this is the first study to fully assess the
performance of these two assays. Jannetto et al. described per-
analyte sensitivities and specificities of a predecessor Nanosphere
assay as 100 and 99.8% for influenza A virus, 100 and 99.1% for
influenza B virus, and 91.7 and 98.4% for RSV and demonstrated
the current automated Nanosphere system to be functionally
equivalent to its predecessor (3). Our RV data are consistent
with those previously published and the package insert. Although
there are no published data on the Simplexa assay, our results
differ from those presented in the package insert. Of note, both
package inserts compare performance to that of direct fluores-
cent-antibody testing and culture, while our study compares the
tests to other molecular methods. Another possible explanation
for differences in observed sensitivities could be regional strain
differences. We have ruled out specimen storage effects by simul-
taneously testing all discrepant results by all methods. As such,
only results obtained after discrepant analysis are included in our
sensitivity and specificity calculations, which we acknowledge
may bias the data in favor of the tests being evaluated.
In our hands, the Verigene RV assay showed sensitivities supe-
rior to those of the Simplexa Flu A/B & RSV kit for influenza A and
influenza B viruses, while the sensitivities for RSV and all specificities
were equivalent. In addition, the Verigene test has the added benefit
of providing influenza A virus subtyping results that may prove help-
ful in epidemiologic investigations, the identification of new variant
influenza strains and/or oseltamivir resistance prediction. These ben-
efits are countered by the relatively low throughput of the Verigene
system. Balancing the need for accurate, rapid results with the need
for high throughput remains a challenge for many laboratories per-
forming molecular detection of respiratory viruses. Depending on
the needs of a given laboratory, one or both of these FDA-cleared tests
may provide the necessary accuracy, time to result, and throughput to
provide meaningful clinical data.
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TABLE 2 Statistical analysis of cycle threshold values of discrepant
samples
Virus and test result n Mean CT (95% CI) P value
Influenza A virus
RV positive 51 24.9 (23.2 26.7) } 0.0039RV negative 2 38.2 (26.1, 50.3)
Simplexa positive 43 23.2 (21.7, 24.7) } 0.0001Simplexa negative 10 35.1 (33.2, 36.9)
Influenza B virus
Simplexa positive 13 28.0 (25.1, 30.9) } 0.0555Simplexa negative 5 32.6 (31.1, 34.1)
RSV
Simplexa positive 82 22.0 (20.9, 23.1) } 0.0001Simplexa negative 5 34.9 (29.3, 40.5)
TABLE 1 Sensitivity of the Verigene RV test and the Simplexa Flu A/B
& RSV kit by virus (n  350)
Test
% Sensitivity fora:
Influenza A virus Influenza B virus RSV
Verigene RV 96.6 (56/58) 100 (21/21) 100 (93/93)
Simplexa 82.8 (48/58) 76.2 (16/21) 94.6 (88/93)
a Values in parentheses are number of samples positive by the test method/number
positive by the reference method.
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